Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 4/20 | 0.48 |
| ▸ | CDK4 | P11802 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 12/20 | 0.47 |
| ▸ | ABL1 | P00519 | 4/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.46 |
| ▸ | CDK1 | P06493 | 2/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.46 |
| ▸ | CDK7 | P50613 | 2/20 | 0.46 |
| ▸ | CDK9 | P50750 | 2/20 | 0.46 |
| ▸ | CCNH | P51946 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | ABL2 | P42684 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18780742 | 0.85 | KDR (0.52) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL18780748 | 0.85 | KDR (0.52) | KDRAURKACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17260999 | 0.85 | KDR (0.49) | CDK2KDRABL1CDK9AURKA | |
| SCHEMBL17261000 | 0.82 | KDR (0.69) | KDRCDK1AURKACYP3A4CYP2D6 | |
| SCHEMBL18763342 | 0.82 | KDR (0.52) | KDR | |
| SCHEMBL18763345 | 0.82 | KDR (0.57) | KDRAURKACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17260977 | 0.82 | KDR (0.56) | KDRAURKACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17261084 | 0.78 | ABL1 (0.49) | CDK2CDK4KDRABL1CCNT1 | |
| SCHEMBL17979821 | 0.76 | KDR (0.47) | KDRABL1CDK7AURKAABL2 | |
| SCHEMBL18763356 | 0.76 | KDR (0.45) | CDK2KDRABL1CDK7CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180057465-A1 | Inhibitors of Necroptosis | CATALYST THERAPEUTICS PTY LTD (AU) | 2018-03-01 | — | — | US | disclosed |
| US-20170114025-A1 | METHODS FOR INHIBITING NECROPTOSIS | CATALYST THERAPEUTICS PTY LTD (AU) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114025-A1 | METHODS FOR INHIBITING NECROPTOSIS | RIPK1, RIPK3, RIPK2 | CDK2 1345/4885CDK4 966/4885KDR 4376/4885 |
| US-20180057465-A1 | Inhibitors of Necroptosis | RIPK3, RIPK1, AIFM1 | CDK2 413/4885CDK4 480/4885KDR 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.